Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat. 2014;21 Suppl 1:1–4.
Article
PubMed
Google Scholar
Sublette VA, Smith SK, George J, McCaffery K, Douglas MW. The Hepatitis C treatment experience: Patients' perceptions of the facilitators of and barriers to uptake, adherence and completion. Psychol Health. 2015;30(8):987–1004.
Article
PubMed
Google Scholar
Myles A, Mugford GJ, Zhao J, Krahn M, Wang PP. Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol. 2011;25(3):135–9.
Article
PubMed
PubMed Central
Google Scholar
Crespo J, Cabezas J, Sacristan B, Olcoz JL, Perez R, De la Vega J, Garcia R, Garcia-Pajares F, Saez-Royuela F, Gonzalez JM, et al. Barriers to HCV treatment in the era of triple therapy: a prospective multi-centred study in clinical practice. Liver Int. 2015;35(2):401–8.
Article
PubMed
Google Scholar
Yehia BR, Schranz AJ, Umscheid CA, Lo Re IV. The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis. Philadelphia: Department of Medicine, University of Pennsylvania, Perelman School of Medicine; 2014. 9((Yehia, Umscheid, Lo Re III).
Google Scholar
Anti-discrimination Board of NSW. C-change: Report of the enquiry into hepatitis C related discrimination. NSW Department of Justice; 2001. www.antidiscrimination.justice.nsw.gov.au/Documents/hepc_report.pdf.
Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet (London, England). 2015;385(9973):1087–97.
Article
CAS
Google Scholar
Department of Health. hepatitis-c-faq. Australian Government; 2016. www.pbs.gov.au/info/publication/factsheets/hep-c/factsheet-for-patients-and-consumers.
Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust. 2016;204(7):268–72.
Article
PubMed
Google Scholar
Moriarty H, Kemp R, Robinson G. Hepatitis services at an injecting drug user outreach clinic. N Z Med J. 2001;114(1128):105–6.
CAS
PubMed
Google Scholar
Gigi E, Sinakos E, Sykja A, Androulakis G, Tanis C, Stayridou V, Tsirogianni E, Zouridakis K, Bellou A-L, Orfanou E, et al. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users. J Addiction Med. 2013;7(1):52–7.
Article
Google Scholar
Moussalli J, Delaquaize H, Boubilley D, Lhomme JP, Merleau Ponty J, Sabot D, Kerever A, Valleur M, Poynard T. Factors to improve the management of hepatitis C in drug users: An observational study in an addiction centre. Gastroenterol Res Pract. 2010;2010. doi:10.1155/2010/261472. Epub 2010 Jul 18.
Kramer JR, Kanwal F, Richardson P, Giordano TP, Petersen LA, El-Serag HB. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol. 2011;106(3):483–91.
Article
PubMed
Google Scholar
Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, Parish B, Burke T, Pak W, Dunkelberg J, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199–207.
Article
CAS
PubMed
Google Scholar
Rossaro L, Torruellas C, Dhaliwal S, Botros J, Clark G, Li C-S, Minoletti MM. Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California. Dig Dis Sci. 2013;58(12):3620–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nazareth S, Kontorinis N, Muwanwella N, Hamilton A, Leembruggen N, Cheng WSC. Successful treatment of patients with hepatitis C in rural and remote Western Australia via telehealth. J Telemed Telecare. 2013;19(2):101–6.
Article
PubMed
Google Scholar
Chen W-L, Chiu W-T, Wu M-S, Hsu M-H, Tsai S-H. Translational research of telecare for the treatment of hepatitis C. BioMed Res Int. 2014;2014:195097.
PubMed
PubMed Central
Google Scholar
Alavi M, Grebely J, Micallef M, Dunlop AJ, Balcomb AC, Day CA, Treloar C, Bath N, Haber PS, Dore GJ. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clin Infect Dis. 2013;57 Suppl 2:S62–9.
Article
CAS
PubMed
Google Scholar
Niederau C, Mauss S, Boker K, Lutz T, Heyne R, Moog G, John C, Witthoft T, Alshuth U, Huppe D. Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice. Eur J Gastroenterol Hepatol. 2014;26(1):65–73.
Article
PubMed
Google Scholar
Myers RP, Cooper C, Sherman M, Lalonde R, Witt-Sullivan H, Elkashab M, Harris P, Balshaw R, Usaty C, Marrotta PJ. Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). Can J Gastroenterol. 2011;25(9):503–10.
Article
PubMed
PubMed Central
Google Scholar
Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. Am J Drug Alcohol Abuse. 2012;38(3):206–12.
Article
PubMed
Google Scholar
Kuo YH, Chen PF, Wang JH, Chang KC, Kee KM, Tsai MC, Lin CY, Lin SC, Tsai LS, Chen SC, et al. Comparison stratagems of post-screening management of anti-HCV-positive community residents: Simple notification, active referral, or accessible medical care. PLoS One. 2015;10(5):e0126031.
Article
PubMed
PubMed Central
Google Scholar
Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stover H, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57 Suppl 2:S129–37.
Article
PubMed
Google Scholar
Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58(5):1598–609.
Article
CAS
PubMed
PubMed Central
Google Scholar
Litwin AH, Harris Jr KA, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, Kaswan D, Gourevitch Marc N, Arnsten JH. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat. 2009;37:32–40. Litwin, Harris Jr., Nahvi, Zamor, Tenore, Arnsten) Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, United States.
Article
PubMed
PubMed Central
Google Scholar
Newman AI, Beckstead S, Beking D, Finch S, Knorr T, Lynch C, MacKenzie M, Mayer D, Melles B, Shore R. Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre. Can J Gastroenterol. 2013;27(4):217–23.
Article
PubMed
PubMed Central
Google Scholar